Silybin and the liver: From basic research to clinical practice

Carmela Loguercio and Davide Festi

Carmela Loguercio, Gastroenterology School-Interuniversity Research Centre on Foods, Nutrition and Gastrointestinal Tract (CIRANAD), 2nd University of Naples, 80131 Naples, Italy
Davide Festi, Department of Clinical Medicine, University of Bologna, 40138 Bologna, Italy
Author contributions: Both authors wrote the manuscript.

Correspondence to: Carmela Loguercio, MD, Gastroenterology School-Interuniversity Research Centre on Foods, Nutrition and Gastrointestinal Tract (CIRANAD), 2nd University of Naples; Via Pansini 5, 80131 Napoli, Italy. carmelina.loguercio@unina2.it

Telephone: +39-81-5666837 Fax:+39-81-5666837

Abstract

Herbal products are increasingly used, mainly in chronic liver disease. Extracts of milk thistle, Silymarin and silybin, are the most prescribed natural compounds, with different indications, but with no definitive results in terms of clinical efficacy. This review analyzes the available studies on the effects of the purified product silybin, both as a free and a conjugated molecule, on liver cells or on experimentally induced liver damage, and in patients with liver disease. We searched PUBMED for articles pertaining to the in vitro and in vivo effects of silybin, its antifibrotic, anti-inflammatory, and antioxidant properties, as well as its metabolic effects, combined with the authors' own knowledge of the literature. Results indicate that the bioavailability of silybin phytosome is higher than that of silymarin and is less influenced by liver damage; silybin does not show significant interactions with other drugs and at doses < 10 g/d has no significant side effects. Experimental studies have clearly demonstrated the antifibrotic, antioxidant and metabolic effects of silybin; previous human studies were insufficient for confirming the clinical efficacy in chronic liver disease, while ongoing clinical trials are promising. On the basis of literature data, silybin seems a promising drug for chronic liver disease.

Keywords: Milk thistle, Silymarin, Liver disease, Hepatic fibrosis, Hepatic inflammation, Radical species

INTRODUCTION

The terms milk thistle, flavonoids, silymarin, and silybin are generally used interchangeably; however, each of these compounds has specific characteristics and actions, with an intrinsic beneficial or toxic effect. In the last 10 years, about 12 000 papers have been published on these substances, used as antioxidants or chemopreventives and anticancer agents, and especially as hepatoprotectants. This publication volume indicates that scientific interest in these molecules, or classes of molecules, is high worldwide. In the US and Europe, about 65% of patients with liver disease take herbal preparations; in Europe, the cost of the use of silymarin reaches $180 million in Germany alone. Despite the wealth of literature, no firm clinical evidence exists to recommend the use of these substances in clinical practice[1-10]. This discrepancy is attributable to various factors, such as quality of clinical trials, heterogeneity of diagnoses, lack of standardized preparations, and frequently inconsistent dosing and outcome parameters. At a time when the use of herbal products is increasing, whether driven by individual choice or industry promotion, in our opinion it is necessary to focus more intently on these compounds that may have beneficial, placebo, or toxic effects.

This review analyzes studies of the effects of the purified product silybin, both as a free and a conjugated molecule, on liver cells or on experimentally induced liver damage, and in patients with liver disease.

DEFINITION AND CHARACTERISTICS OF SILYBIN

As reported, silybin and silymarin are not synonymous[1,3,6]. Silymarin is a complex of at least seven flavonolignans that are the most common class of compounds present in milk thistle extract, and one flavonoid, taxifolin. The relative abundance of each compound may vary depending on the source of botanical material, supplier, and extraction processes. Silybin represents about 50% to 70% of the silymarin extract. Silybin can be resolved into two 1:1 diastereoisomers, silybin A and silybin B. In addition, silybin may be present as isosilybin, a 1:1 mixture of two diastereoisomeric compounds, isosilybin A and isosilybin B[11-17]. The concentrations of silybin in the main pharmaceutical products containing silymarin present in the US and other countries range from 20% to 40%[16].

PHARMACOKINETICS AND PHARMACODYNAMIC ASPECTS

Flavonolignans are known for their poor and erratic bioavailability; for example, silymarin absorption rate levels vary between 20% and 50%. Silybin has been separated commercially as a pure substance[11-16], and the study of silybin pharmacokinetics properties using an HPLC method has shown that the concentration-response relationship is linear over a concentration range of 0.5-100 μg/mL[16]. After administration to rats, the disposition of silybin in the plasma and bile fluid is due to rapid distribution and equilibrium between the blood and hepatobiliary system, and the bile levels of unconjugated and total silybin are greater than those in plasma[18-22].

Similarly to other flavolignans, limiting factors for the use of silybin are its low solubility in water, low bioavailability, and poor intestinal absorption. To counteract this aspect, different more soluble derivatives of silybin have been synthesized, such as silybin bis-hemisuccinate, β-cyclodextrin complex, silybin-N-methyl-glucamine, silybin 11-O-phosphate, and silybin-phosphatidylcholine. Another strategy for improving silybin solubility is represented by the enzymatic synthesis of its β-glycosides, such as silybin β-galactoside, silybin β-glucoside, silybin β-maltoside, and silybin β-lactoside. A soluble silybin prodrug has been finally synthesized with a high aqueous soluble polymeric carrier (polyethylene glycol)[23-30].

Some conjugations may in part affect the activity of silybin. For example, the radical-scavenging activity of the silybin 20-O-β-D-glucuronide is considerably lower than that of free silybin. In contrast, a considerable increase in radical-scavenging activity is observed in the other silybin, 7-O-β-D-glucuronide, in which position C-20 is free. The increase in the radical-scavenging activity of this latter conjugate cannot be simply ascribed to the addition of the glucuronyl moiety. The change in antiradical activity is, therefore, the result of the overall structural change. It is also quite interesting that one diastereoisomer of silybin (B) undergoes conjugation faster than the other (A); this difference indicates that the two silybin diastereoisomers are metabolized at different rates. These findings will aid the development of improved silybin formulations designed to inhibit the C-20 conjugation or, alternatively, to contribute to a modified dosage scheme that maintains free plasma silybin at sufficient levels[31-35]. Both free and conjugated silybin have a rapid plasma and tissue distribution that reaches maximum levels within one hour after 50 mg/kg silybin administration in mice[36]. The protein binding of silybin in rat plasma is 70.3% ± 4.6%[21].

In humans, the pharmacokinetics of silybin was evaluated after the administration of variable doses of silymarin, pure silybin, and silybin conjugated with phytosome in healthy volunteers. Hoh et al[37] for the first time identified the silybin plasma metabolites and measured the silybin tissue levels in humans who had ingested silybin. They demonstrated that silybin undergoes multiple conjugation reactions in humans and clearly identified the conjugated species: silybin monoglucuronide, silybin diglucuronide, silybin monosulfate and silybin glucuronide sulfate. The administration in humans of 240 mg of pure silybin induces a peak concentration of 240 ± 54 ng/mL in about 2 h that persists for 4 h. After administration of a single oral dose of 560 or 600 mg silymarin (about equivalent in total to 240 mg of silybin), the fractions of the free, sulfated, and glucuronidated silybin in human plasma are about 17%, 28%, and 55% of the total dose, with a higher plasma percentage of glucuronidated silybin B (71%) than of glucuronidated silybin A. The total percentage of dose recovered in urine, as free and conjugated, is very low, ranging from 1% to 7% of the dose (mean: 2.8 ± 0.6 ng/mL)[29,38-42]. The complex silybin phytosome (silybin + phosphatidylcholine) was recently formulated with the addition of vitamin E (Indena, IBI-Lorenzini spa Italy: Realsil®). This conjugation induces a greater solubility of silybin, as reported in Table 1. In 12 healthy volunteers aged 20-53 years, silybin was administered as Realsil® in two pharmaceutical forms (capsules and granules, both corresponding to 47 mg of silybin). Data were compared to those obtained by administering, in a cross-over manner after 1 wk of wash-out, a silymarin capsule containing 58 mg of silybin and silymarin granules containing 80 mg of silybin[43]. As summarized in Tables 1 and 2, the global results of the pharmacokinetic analysis indicated that the bioavailability of silybin phytosome is much higher than that of silymarin.

Table 1

Pharmacokinetics of silybin phytosome and silymarin in healthy participants[38-43]

	Silybin phytosome	Silymarin
Peak concentration (ng/mL)	298 ± 96	102 ± 22[a]
Time of peak (h)	1.6 ± 0.3	1.4 ± 0.3
Mean residence time (h)	3.6 ± 0.4	3.5 ± 0.4
AUC (ng/mL/h)	881 ± 207	257 ± 66[b]

[a]$P < 0.05$,
[b]$P < 0.01$. NB: The analyses were performed using HPLC.

Table 2

Pharmacokinetics of silybin after administration to 12 healthy volunteers as silymarin or silybin-phosphatidylcholine-vitamine E complex (RA)[43]

Product	Cmax (ng/mL)	Tmax(h)	AUC (ng/mL per hour)
RA granules (47 mg silybin)	213 ± 166	0.5	246 ± 114
RA capsules (47 mg silybin)	117 ± 93	1.0	161 ± 85
Silymarin gran (58 mg silybin)	18 ± 17	0.5	25 ± 18
Silymarin caps (80 mg silybin)	5 ± 7	1.0	11 ± 5

EFFECT OF LIVER DAMAGE ON PHARMACOKINETICS OF SILYBIN

In patients with well-compensated liver cirrhosis, silybin was administered as silybin phytosome at a dose of 120 mg × 3 /d, or as silymarin containing 84 mg of silybin 4 fold/d. The results showed that liver cirrhosis does not modify the kinetics of silybin and that in liver patients, the bioavailability of silybin is higher when it is administered as a phytosome adduct[44]. Similar data were obtained in rats with experimentally induced cirrhosis[45]. Table 3 summarizes the data obtained in humans.

Table 3

Comparison between silybin phytosome and silymarin pharmacokinetics in patients with liver cirrhosis[44]

	Silybin phytosome (360 mg)	Silymarin (336 mg)
C_{max} (ng/mL)	860 ± 166^b	83 ± 15
Tmax (h)	2.7 ± 0.7^b	2.6 ± 2.1
/2 (h)	3.3 ± 0.7^b	2.6 ± 0.4
AUC	515 ± 665^b	262 ± 39
Total bioavailability	252 ± 39^b	19 ± 23

$^bP < 0.001$.

More recently, the pharmacokinetics of silybin has been evaluated in patients with chronic hepatitis [hepatitis C virus (HCV) or non-alcoholic fatty liver disease (NAFLD)] and compensated liver cirrhosis[46,47]. A single, 600 mg p.o. dose of milk thistle extract was administered to healthy volunteers and to three patient cohorts, and blood samples were obtained over 24 h. Silybin A and B accounted for 43% of the exposure to the sum of total silymarin flavonolignans in healthy volunteers and only 31% to 38% in liver disease cohorts as a result of accumulation of silychristin (20%-36%). Area under the curve (AUC, 0-24 h) for the sum of total silymarin flavonolignans was 2.4, 3.3, and 4.7-fold higher for the HCV or NAFLD ($P \leq 0.03$) and HCV cirrhosis cohorts ($P \leq 0.03$), respectively, compared with healthy volunteers. Silymarin kinetics was correlated with plasma levels of caspases as an index of liver inflammation; caspase 3/7 activity correlated with the AUC (0-24 h) for the sum of all silymarin conjugates among all participants ($R^2 = 0.52$) and was 5-fold higher in the HCV cirrhosis cohort ($P \leq 0.005$ versus healthy participants). These findings suggest that the presence of liver damage, particularly as chronic inflammation, may affect the bioavailability of the different components of silymarin, possibly explaining the low beneficial effects of flavonoids in patients with liver damage.

Interactions and toxicity

There are substantial differences between silymarin and silybin in their interactions with metabolizing enzymes, and the reasons for these differences remain unknown. Silybin alone or as silybin β-galactoside, β-glucoside, β-lactoside, or β-maltoside at a final concentration of silybin 100 μmol/L has been tested *in vitro*. Under these conditions, silybin showed slow inhibitory effects ($IC_{50} > 200$ μmol/L) on marker substrates of CYP2E1, CYP2D6, CYP2C19, and CYP2A6. Silybin and silybin β-glycosides did not induce expression of CYP1A2 and CYP3A4 and did not affect the inducible expression of either of these enzymes[48-53].

In *in vivo* work, Sridar et al[54] investigated metabolic interactions involving silybin at doses ranging from 25 to 250 μmol/L and substrates metabolized by CYP3A4 or CYP2C9, showing that silybin may be a modulator/inactivator of P450s 3A4 and 2C9. What remains to be elucidated is whether this effect is brought about by competition at the site or inhibition for substrate binding and for metabolism at a particular binding pocket in the active site; another possibility is that it results from a conformational change in the active site. Despite these results, silybin has shown no effect on the metabolism of indinavir[55,56], which is mediated by CYP3A4, and others[57-60] have documented that silybin, at a concentration of 100 μmol/L, has no effect on either basal or inducible expression of CYP3A4 mRNA.

In any case, the silybin-drug interaction of these enzyme substrates is not clinically relevant, and the inhibitory effects of silybin occur only at concentrations that massively exceed the physiologically used doses[60-62]. *In vitro*, silybin inhibits the UGT glucuronyl transferases UGT1A6 and UGT1A9, but it is 14- to 20-fold more selective for UGT1A1[48,49,61-64] (see Table 4 as summary). The clinical relevance of this phenomenon is presently unknown because there are no published reports indicating the existence of a clinical interaction with bilirubin. UGT1A1 is the only enzyme responsible for bilirubin glucuronidation, and it contributes to the glucuronidation of several drugs. In animals, silybin affects the hepatobiliary elimination of various drugs[52,53,57,58,64]; oral feeding of pure silybin at doses of 100 and 200 mg/kg/bw/d showed a moderate to highly significant increase in both glutathione-S-transferase and quinine reductase activities in the liver, lung, stomach, skin, and small bowel in a dose- and time-dependent manner[58]. Recently, Flaig et al[27] provided the best evidence that silybin can be administered to humans at doses producing anticancer-relevant concentrations, with minimal or no side effects. That study employed the largest doses ever used, ranging from 2.5 to 20 g of silybin-phosphatidylcholine (Indena's Siliphos® "silybin phytosome"), given daily in three divided doses for 4 wk to 13 men with a history of prostate carcinoma. At a dose escalation from 15 to 20 g/d, silybin was discontinued because of asymptomatic hyperbilirubinemia, most likely because of inhibition of the glucuronyl transferase UGT1A1. However, in all patients, this mild hyperbilirubinemia improved with treatment cessation.

Table 4

Interference of silybin with cytochromes[48-64]

Interference	Possible interference	No interference
UGT1	CYP3A4	CYP2E1
	CYP2	CYP2D6
		CYP2C19
		CYP1A2
		CYP2A6

The limitations of available clinical trials with regard to establishing safety are the same as those for establishing efficacy. Clinical trials testing safety are poor predictors of the fate of extracts in real-world settings, where patients ingest multiple drugs and herbs, take different formulations of the same

product, and add alcohol and other compounds, often for extremely long periods. In the randomized trials that reported adverse effects, their frequency was approximately equal in the silybin and control groups. The majority of the observed adverse events were unrelated to the product or difficult to separate from the concomitant disease, and in available reports, causality is rarely addressed. There are no safety data in children or older adults, as there are no reported studies in children and very few studies that included patients older than 65 years. Adverse effects associated with oral ingestion of silybin include mainly gastrointestinal problems, but these are rare. Headache/dizziness and pruritus were reported in one clinical trial. Asymptomatic liver toxicity has been observed in recent clinical trials performed in cancer patients, in whom hyperbilirubinemia and increases in alanine aminotransferase (ALT) levels were observed; however, these effects were present only when very high dosages of silybin phytosome (between 10 and 20 g/d) were used. At high doses, a laxative effect of silybin phytosome is possible because of increased bile secretion and bile flow. Mild allergic reactions have also been noted, but they were not serious. Therefore, the available data indicate that milk thistle has few side effects when doses lower than 5 g/d are used, with possible adverse effects at doses greater than 10 g/d[6,7,62].

The documented effects of silybin in basic research

In liver cells, as well as in other types of cells, the common effects of silybin may be summarized as follows: (1) Antioxidant; (2) Direct and/or indirect (through the antioxidant capability) modulator of inflammation and fibrogenesis; and (3) indirect and/or direct modulator of some intrahepatic metabolic pathways.

Antioxidant action

The antioxidant effects of silybin have been demonstrated in all cells studied. Silybin acts as an antioxidant because it inhibits radical formation, binds some radical species (scavenger), interferes with lipid peroxidation of membranes (and therefore modulates membrane permeability), and increases the intracellular content of scavengers[65]. In fact, in the presence of oxidative and nitrosative stress, silybin inhibits the formation of superoxide anion radicals and of nitric oxide (NO), increases ATP content through the phosphorylation of ADP, decreases the content of malondialdeyde (MDA) and totally abolishes the decrease of glutathione, of superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase[66-73]. These results, which are dose-dependent, have been documented in isolated rat Kupffer cells, hepatocytes, HEPG2 cells, isolated mitochondria from rat hepatocytes, and in models of ischemia-reperfusion of rat liver. In experimentally induced liver damage, one hour after intragastric administration to rats of conjugated silybin (0.6 g/kg bw), the content of silybin in the microsomes measured using a specific HPLC assay was approximately 2.5 μg/mg of protein, corresponding to a final concentration of 10 μmol/L of silybin. Under these conditions, lipid peroxidation, mitochondrial permeability and respiration, and membrane potential as well as cell death were reversed by silybin, particularly if it was conjugated as silybin + phosphatidylcholine. This last compound, at a dose of 20 μmol/L, directly scavenges hydroxyl, hydroxyethyl, lipodienyl, methyl, and trichloromethyl radicals[74,75].

Finally, silybin acts as an antioxidant because it also serves as an iron chelator[76-78]. More recently, it has been suggested that dehydrosilybin (DHS), an oxidized form of silybin, has greater antioxidant activity than silybin (about three times better), probably because of the presence of unsaturated bonds that contribute to hydrogen-donating capacity. The better scavenger activity of DHS may also be the result of its greater ability to react with cell membranes because it has higher lipophilicity than silybin[32,65].

Table 5 summarizes the main antioxidant effects of silybin.

Table 5

Antioxidant effects of silybin[65-75]

Doses	Cells	Targets
From 10 to 100 μmol/L	Hepatocytes	Decreased formation of reactive oxygen species from mitochondria; iron chelator
	HepG2	Decreased formation of superoxide anion
Mean dose with documented effects: 20 μmol/L	Kupffer cells	Decrease of NO production
	Monocytes	Scavenger of lipodienyl, methyl, trichloromethyl radicals
	Endothelial cells	Decrease of hydrogen peroxide concentration
	Cancer cells	Block of membrane lipid peroxidation

Anti-inflammatory action

In general terms, silymarin and silybin interfere with the NF-κB-controlled transduction cascade. NF-κB is an inducible and ubiquitously expressed DNA-binding protein, acting as a transcription factor for genes involved in inflammation, cell survival, differentiation, and growth[79,80]. In unstimulated cells, NF-κB is sequestered in the cytoplasm by interaction with inhibitory protein 1 κ B α (IκBα). Upon activation from oxidative stress, NF-κB dissociates from IκBα, and IκBα is degraded. NF-κB translocates to the nucleus and, through kinase phosphorylation, drives the activation of genes supporting inflammation. Consistent with its antioxidant activity, silybin has been demonstrated to inhibit NF-κB activation and translocation through suppression of IκBα phosphorylation and degradation[81-83]. In an acute model of liver damage in which mice were treated with concanavalin A, silybin reduced plasma levels of transaminases and the plasma and liver content of pro-inflammatory cytokines, inhibited hepatic NF-κB activation, and increased plasma and tissue levels of IL-10[84]. In rats with dimethyl-nitrosamine-induced chronic liver damage, silybin conjugated with phosphatidylcholine and vitamin E (Realsil®, Ibi-Lorenzini, Italy) administered by gastric gavage could prevent loss of body and liver weight, as well as reducing the degree of liver injury, as determined by ALT values and necroinflammatory scores. This outcome was associated with reduced hepatic stellate cell activation and proliferation both after 1 and 5 wk of treatment[85]. The anti-inflammatory action of silybin is also related to its interference with multiple cytokine-induced signaling pathways to down regulate inducible nitric-oxide synthase (iNOS) expression[86-88]and to the inhibition of cyclooxygenase (COX)-2 expression and activity and leukotriene formation in human platelets, white blood cells, and endothelial cells. Finally, silybin inhibits activation of the protein kinases and of a c-jun N-terminal kinase[89-92].

In addition to its antioxidant and anti-inflammatory actions, silybin also shows an antiviral effect. In fact, at a concentration of 20 μmol/L, it inhibits the protein expression and the replication of HCV virus in infected polymorphonucleated cells derived from patients with chronic HCV infection[93-95].

Antifibrotic action

In an *in vitro* model of human hepatic fibrogenesis, silybin demonstrated both direct and indirect antifibrotic properties. In fact, in stellate cells from human liver, silybin reduced platelet-derived growth factor (PDGF)-induced DNA synthesis and cell proliferation at a dose of 25 μmol/L. Silybin also reduced PDGF-induced cell migration in a dose-dependent fashion. Finally, pre-treatment with 25-50 μmol/L of silybin significantly reduced the TGF-β-induced *de novo* synthesis of procollagen type I in cell supernatants[96].

To investigate the role of silybin in modulating the pro-inflammatory properties of hematopoietic stem cells, cells were stimulated with IL-1β (20 ng/ml), a potent pro-inflammatory cytokine; silybin inhibited, in a dose-dependent manner, IL-1-induced synthesis of human MCP-1 (monocyte chemoattractant protein 1) and human IL-8 as detected in cell supernatants. This effect was related to the effect of silybin on the inhibition of IκBα phosphorylation and to its capability to inhibit ERK, MEK, and Raf phosphorylation at any concentration used[96]. Antifibrotic effects were also documented in experimental animals and in humans[85,97-99].

Table 6 summarizes the main anti-inflammatory and antifibrotic effects of silybin.

Table 6

Anti-inflammatory/antifibrotic effects of silybin[79-99]

Doses	Cells	Targets
From 5 to 50 μmol/L	Hepatocytes	Inhibition of NF-κB-mediated signaling
Mean: 15 μmol/L	Endothelial cells	Suppression of IκBα phosphorylation
	Platelets	Inhibition of protein kinase kinase
	Cancer cells	Inhibition of c-jun N-terminal kinase
	Phagocytes	Inhibition of leukotriene formation
	Stellate cells	Inhibition of release of cytochrome c
	HepG2	Inhibition of ERK, MEK, and Raf phosphorylation; inhibition of release of caspase 9 and 3, IL-8, and of PDGF- and TGF-β-mediated signaling; decrease of MMP2; increase of TIMP2; inhibition of HCV replication

Metabolic effects

Silybin interferes with some mechanisms of action of insulin. In fact, it modulates the uptake of glucose in adipocytes by blocking the insulin-dependent glucose transporter 4. In rat hepatocytes, silybin, in concentrations ranging from 25 to 100 μmol/L, lowers glucose formation from different gluconeogenic substrates through an inhibitory effect on pyruvate kinase activity[100]. As previously reported in cultured hepatocytes, low doses of silybin reduce reactive oxygen species formation from mitochondria; this reduction leads to a decrease in oxidation of carbons arising from glycolysis[101]. Moreover, silybin inhibits, in a dose-dependent manner, gluconeogenesis and glycogenolysis, both in basal conditions and after a glucagon-dependent stimulation, by blocking glucose-6-phosphate hydrolysis. This effect was demonstrated using different substrates, such as dihydroxyacetone, lactate/pyruvate, glycerol, and fructose[102] (Table 7).

Table 7

Effects of silybin on hepatic metabolism of glucose at doses of 25-100 μmol/L in hepatocytes[100-102]

Doses	Cell	Targets
25-100 μmol/L	Hepatocytes	Inhibition of pyruvate kinase
		Inhibition of glycolytic flux
		Inhibition of glucose-6-phosphate hydrolysis
		Inhibition of glucose-6-phosphatase

In an animal model of type 1 diabetes mellitus[103], in a 6-mo, double-blind, randomized trial in patients with poorly controlled non-insulin-dependent diabetes mellitus and alcoholic liver disease[104], and in a randomized, double-blind, placebo-controlled trial in patients with type II diabetes[105], silybin significantly affected plasma levels of glucose and triglycerides, with a trend toward lower hemoglobin A1c levels.

Other effects on cellular signaling

In cancer cells, silybin alters cell cycle regulators and induces apoptosis, both through antioxidant and anti-inflammatory properties and through the inhibition of growth factor receptor-mediated mitogenic and cell survival signaling, particularly related to the activation of tyrosine kinases[106-111]. PDGF receptor (PDGFR), epidermal growth factor receptor (EGFR), Bcr-Abl, and KIT are examples of tyrosine kinases overexpressed in most human cancers. Silymarin or silybin are particularly effective in inhibiting EGFR signaling with suppression of cyclin-dependent kinase expression (i.e. CDK4) and up regulation of CDK inhibitors (CDKIs). These effects lead to G1 and G2-M arrest in cancer cells[112-119], as recently confirmed in a model of human colon cancer[120,121]. In fact, at a dose ranging from 40-75 μmol/L, silybin significantly inhibited cell proliferation through cell cycle arrest *via* inhibition of cyclin promoter activity.

Because it inhibits constitutive NF-κB activation, silybin can induce apoptosis, consistent with a significant decrease in its nuclear level of p65 subunit. In addition, it activates caspase 3 and caspase 9 and decreases survivin levels[122].

Angiogenesis refers to the growth of capillary vessels from existing blood vessels and is considered obligatory for the growth and progression of solid tumors. Angiogenesis critically depends on several conditions; in fact, endothelial cells must: (1) proliferate to provide the necessary number of cells for the growing vessels; (2) secrete matrix metalloproteinases (MMPs), which are required to break down surrounding tissue matrix; and (3) be capable of movement and migration. In addition, the angiogenic stimuli like hypoxia and the production of angiogenic cytokines, such as vascular endothelial growth factor (VEGF), must be sustained. Silybin treatment decreases secreted VEGF levels and shows a strong, concentration-dependent inhibition of capillary tube formation on matrigel, retraction, and disintegration of preformed capillary network, inhibition of matrigel invasion and migration, and a decrease in MMP-2 secretion[92,106-122].

Table 8 summarizes the main cellular signaling affected by silybin.

Table 8

Other effects of silybin on cellular signaling[106-122]

Induction of apoptosis through an inhibition of IGF-IR
Down regulation of survivin and an increase in p53 expression
Block of cycle-regulator cyclins and promoter activities
Decrease of MMP-1 production
Decrease of angiogenesis
Inhibition of VEGF expression
Inhibition of HIF-1α
Increase of IGFBP-3

The use of silybin in the clinical setting: efficacy and suggestions

The use of silymarin in the clinical setting has a long history; in its native Mediterranean region, it has been employed for liver damage since the Greco-Roman era. As mentioned in the introduction, "herbal therapy" use is consistently increasing worldwide, and some of the most common herbal supplement preparations are derived from the milk thistle plant (*Silybum marianum*). Despite a long history of its use and the large number of people who consume this substance, no conclusive data on its clinical efficacy can be identified. In fact, only a few well designed clinical trials have been performed. Most studies have been conducted using silymarin and with inclusion of patients with alcoholic or viral cirrhosis. Stickel et al[8] identified the 10 main controlled trials conducted in liver patients, with numbers of patients ranging from 20 to 200 and doses of silymarin ranging from 210 to 450 mg/d for 7 to 730 d. These clinical studies generally have suffered from the same shortcomings found in many other trials on herbal medicines, such as a small sample size, lack of appropriate randomization and of

allocation concealment or blinding, very different periods of treatment, lack of information about type and dose of extract used as well as product characterization, ill-defined patient population, and a lack of etiology, severity of disease, and discussion of potential confounders.

We could argue that the history of studies on silybin reflects, in part, the epidemiological history of liver diseases. When liver cirrhosis was the only clearly identified manifestation of liver damage and alcohol was the only known pathogenetic factor, silymarin and other plant extracts represented the most frequently used drugs. Knowledge about the pathogenetic relationships between hepatitis viruses and liver damage induced researchers and industry to focus attention on antiviral drugs. In response to the discovery of metabolic liver diseases, as well as increased knowledge about the cellular and subcellular mechanisms of both induction and progression of liver damage, researchers in academia and industry have begun to reappraise natural products and to evaluate their therapeutic efficacy using appropriate methods.

The clinical experience with silybin is mainly related to its properties as a detoxifying agent and as a hepatoprotective compound in different acute and chronic liver diseases.

Silybin as a detoxifying and hepatoprotective substance

Several chemotherapeutic agents are metabolized by the liver and can exert hepatotoxicity, with the net result of drug reductions or withdrawal. Chemotherapeutic agents that are likely to produce hepatotoxicity include dactinomycin, daunorubicin, docetaxel, gemcitabine, imatinib, 6-mercaptopurine, methotrexate, and oxaliplatin. Cancer patients taking these therapies often self-medicate with milk thistle because of its reputation as a liver protectant. Clinicians also prescribe it to cancer patients for the same purpose. The rationale of milk thistle use is to provide support to the liver while it performs multiple functions, including responding to the increased metabolic demands caused by tumor growth, assisting in metabolizing products generated when a tumor is killed or reduced by chemotherapy and radiation, and aiding in the processing of drugs prescribed to cancer patients.

Silybin is also considered a potent inhibitor of human intestinal β-glucuronidase, blocking the release and reabsorption of free xenobiotics and their metabolites from their glucuronide conjugates. Because the liver is the primary organ that cleanses and detoxifies the blood, many detoxification programs include a component of liver support or what is often called liver cleansing. For these reasons, silybin is commonly included in detoxification regimens[6,7,62,108-111]. However, only one randomized, double-blind study has reported the effects of milk thistle in patients receiving cancer therapy; 50 children with acute lymphoblastic leukemia and grade 2 or higher hepatic toxicity were randomized to receive a milk thistle supplement (Siliphos, Thorne Research, Dover, Idaho) (5.1 mg/kg/day) or placebo for 28 days. The authors reported significant reductions in AST levels ($P < 0.05$) and a trend toward a significant reduction in ALT levels ($P < 0.07$). A significantly larger number of children in the milk thistle group developed a > 50% reduction in total bilirubin at day 28 compared to placebo ($P < 0.0069$)[123].

Silybin in acute liver damage

The administration of silybin within approximately 48 h after poisoning produced by the mushroom *Amanita phalloides* (death cap) seems to be an effective measure to prevent severe liver damage[124]. A retrospective analysis of 205 cases of clinical poisoning from 1971 to 1980 documented the efficacy of milk thistle silybin extract in increasing survival rates in adults and children exposed to this potentially lethal mushroom[125]. In January 2007, six family members in California suffering from aflatoxin poisoning caused by *A. phalloides* mushrooms were treated with intravenous milk thistle,

provided by Madaus Pharma (Brussels, Belgium; division of Madaus AG, Cologne, Germany). The US Food and Drug Administration granted permission for the use of milk thistle after considering that all patients were at high risk of dying of liver failure. Ultimately, one of the six patients died, while the others had a full recovery after treatment. A case report mentions that silybin may offer protection from liver toxicity caused by the pharmaceutical drug phenytoin[126].

Silybin in chronic liver disease

The various flavonoid compounds that are included in the general term "milk thistle" have been recognized as a "safe and well-tolerated herb" with a limited adverse event profile[1-10]. As previously reported, the majority of studies have been conducted using silymarin and including patients with alcoholic or viral cirrhosis. The Cochrane Collaboration group[4,127] evaluated the studies related to the use of silymarin/silybin in patients with different types of acute and chronic liver diseases. Various items were analyzed to define the quality of trials, such as the number of participants, the criteria of randomization, the blinding, the modalities of follow-up, and the statistical methods. From 1,831 references, 67 publications addressed patients with alcoholic and/or hepatitis B or C liver diseases treated with milk thistle; of these, only 26 were selected according to the agreed criteria, and these were associated with 13 trials. The active treatment consisted of silymarin per os in 10 randomized clinical trials, silybin phytosome per os in two randomized clinical trials, and silybin + phosphatidylcholine in one randomized clinical trial. The Cochrane Collaboration studies concluded that milk thistle does not seem to significantly influence the course of the disease in treated patients. However, all causes of mortality were reduced by 50% in patients with alcoholic liver disease without HCV antibodies who took milk thistle extracts compared to placebo ($P < 0.05$); in trials that studied liver-related mortality, there was a significant effect of silybin (relative risk, 0.50; 95% CI 0.29 to 0.88; $P = 0.02$) [4,8,9,127,128].

Seeff et al[5,129] examined the spontaneous use of herbal products in the US in patients affected by HCV chronic infection, including non-responders to a previous treatment with interferon and ribavirin. In 1145 patients, about 50% used herbal products; of these, silybin was used by 70%. Even if no changes in liver tests and/or in HCV-RNA serum levels were observed, the univariate analysis documented a lower incidence of symptoms and a better quality of life in patients who consumed silybin relative to those who did not. On multivariate analysis, adjusted for age, gender, educational status, alcohol use (n. drinks/d), physical activity, body mass index, and smoking, silybin positively affected more than one aspect of quality of life. An examination of the total number of patients treated with silymarin/silybin in both well-conducted trials and in pilot studies with a high quality identified about 2000 patients with liver cirrhosis or with chronic hepatitis of different etiology, with a mean duration of treatment of six months and a dose of silybin ranging from 160 to 360 mg/d (except in two cases, see below).

The main results regarding the efficacy of silybin in liver disease patients are summarized as follows.

In the past, most studies were focused on liver cirrhosis, particularly alcoholic cirrhosis, and the efficacy of silybin was evaluated in terms of improvement in liver test abnormalities and/or in mortality rate (see above for results)[126-128]. Silybin β-cyclodextrin has been studied as an antidiabetic drug in patients with alcoholic liver disease and concomitant non-insulin-dependent diabetes mellitus; in these patients, the drug (at a dose of 135 mg/d) did not influence liver function test results or insulin secretion but significantly reduced fasting glucose ($P < 0.03$) and serum triglyceride levels ($P < 0.01$) compared to placebo. The effects seem to be related to a reduction in insulin resistance[104].

More recently, studies have focused on chronic hepatitis, particularly that induced by HCV. Silybin phytosome, at a dose ranging from 240 mg/d to 942 mg t.i.d. (the highest dose used in patients with liver damage) was well tolerated without adverse effects and significantly improved liver damage as expressed by transaminase levels, oxidative stress (serum malondialdehyde levels) and both ferritin serum levels and iron global body storage[130-138]. Today, the attention of researchers is focused on a possible antiviral effect of silybin against HCV infection.

Polyak et al[95] tested the anti-inflammatory and antiviral action of different extracts from silymarin on polymorphonuclear cells from patients with chronic HCV infection, documenting an anti-inflammatory and antiviral effect of milk thistle extract, mainly for silybin, which presented the strongest anti NF-κB and anti-HCV replication effect. Ferenci et al[139] and Biermet et al[140] have demonstrated that silybin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. These studies also showed that very high doses of silybin i.v. (from 5 to 20 mg/kg/d for 14 d) were free of toxic effects.

Finally, non-alcoholic fatty liver disease (NAFLD) may occur as an expression of a metabolic syndrome or in association with HCV chronic infection. The simultaneous presence of NAFLD in this latter group of patients may negatively affect the progression of fibrosis and the response to antiviral treatment. Patients affected by primitive NAFLD and/or chronic HCV-related hepatitis in combination with NAFLD, all non-responders to previous antiviral treatment, were treated with four pieces/d of the complex silybin-vitamin E-phospholipids corresponding to about 200 mg of pure silybin/d for three or six months. The treatment induced a significant reduction of plasma markers of chronic inflammation (C-reactive protein and cytokines), metabolic parameters (triglycerides, cholesterol, insulin resistance), liver tests (transaminases and gamma-glutamyl transpeptidase), degree of ultrasonographic liver steatosis and, finally, of main indices of liver fibrosis TGF-β, hyaluronic acid and metalloproteinase 2) [99,141,142].

In a rodent model of non-alcoholic steatohepatitis, the same silybin phospholipid complex prevented mitochondrial dysfunction[143], and preliminary results in a large, multicenter Italian trial vs. placebo indicate that complex silybin-vitamin E-phospholipids significantly improved liver damage in patients with NAFLD and markers of liver fibrosis in patients with HCV chronic hepatitis[144].

In Table 9 the main studies performed with silybin are reported and discussed.

Table 9

Main studies performed by using purified silybin as drug

Authors	Type of study, number of patients	Drug used, dose and duration of treatments	Outcomes	Results	Clinical relevance
Vailati et al[146]	A phase II randomised, open trial on 60 patients with chronic alcoholic or viral hepatitis	Three doses (160, 240, 360 mg) of silybin and phosphatidylcholine (IdB 1016, Indena, Italy) for two weeks. No placebo or no intervention group was used	Liver tests	Improvement of liver enzymes with all used doses	Scarce
Buzzelli et al[147]	Double blind with identical placebo. Twenty patients with HBV and/or HCV chronic active hepatitis	IdB1016 (complex with phosphatidylcholine and silybin) two capsules, twice a day (equivalent to 120 mg of silybin in each capsule) (480 mg/d). Duration of treatment and of follow-up: two months in total	Mortality. Liver biochemistry	Improvement of liver enzymes and bilirubin	Scarce

Open in a separate window

CONCLUSION

The data reported in this review clearly indicate the increasing interest in silybin and its compounds as well as the continuous improvement in knowledge about the molecular actions of this substance. However, in the clinical setting, there is currently a lack of definitive data about its efficacy in patients with chronic liver disease. The only well-defined finding is the absence of adverse events at high doses. Generally, all clinical studies on herbal products suffer from similar limitations, in part related to the fact that well-designed trials require resources and natural products industries do not sponsor them with significant budgets. In addition, in the majority of cases, herbal products differ from pharmaceutical compounds because multiple ingredients could act through multiple pathways to therapeutically affect the host. In the case of silybin, clinical studies on the pure extract and/or its derivatives are few and with a limited number of patients. Silybin is the most active flavonolignan in silymarin, and most

capsules are standardized to this compound, but many variations of complex mixtures and single extracts are available and may critically affect clinical outcome. A full phytochemical and biological profile is preferable before commencing any clinical study. Today, analytical techniques that examine a suite of compounds, including their respective ratios, provide a more rational approach to authentication and quality assessment of the products. There must be assurance that the administered dose increases plasma and/or target tissue concentrations consistent with those required to produce effects *in vitro*. One primary fault of many clinical studies of botanicals is that adequate pharmacokinetic analyses are not completed before initiating efficacy trials. Some botanicals may fail in efficacy trials, not because the botanical is itself without activity but because the dosing was not sufficient to achieve pharmacologically meaningful concentrations.

Several silybin clinical trials are ongoing at this time (see also online at www.nccam.nih.gov). In addition, manufacturers of milk thistle extracts are conducting clinical trials with their own products that will elucidate the effects of specific preparations.

There is a need to enhance the funding opportunities to evaluate these long-used products with evidence-based knowledge, but there is also a need to reiterate Kroll et al[60], "As biological studies progress, it remains important to make the distinction between silymarin and silybin and their respective and distinct compositions". This latter point should also be considered when clinical investigators turn to pooling existing studies for meta-analyses. The epidemiology of chronic liver disease is changing worldwide: viral infections are declining, and patients with HCV/HBV chronic hepatitis are older; NAFLD and alcoholic liver diseases are increasing, and generally patients with these pathologies are younger. Finally, alcohol-related problems, metabolic disruptions, and viral infections frequently coexist in the same patient[145]. Therefore, in clinical practice, there is the need for drugs that can be used in the long term without serious adverse events. Researchers should definitively demonstrate if silybin has potential in this regard. Lastly, the absence of significant adverse effects of silybin even at high doses, the good compliance by the patient, the availability of a purified form of the compound, represent characteristics that allow to obtain commercially available products containing almost 600 mg of pure silybin to ensure a good concentration in tissues.

Footnotes

Peer reviewer: James Neuberger, Professor, Liver Unit, Queen Elizabeth Hospital, Birmingham B15 2TH, United Kingdom

S- Editor Tian L L- Editor O'Neill M E- Editor Ma WH

References

1. Simánek V, Kren V, Ulrichová J, Vicar J, Cvak L. Silymarin: What is in the name...? An appeal for a change of editorial policy. Hepatology. 2000;32:442–444. [PubMed] [Google Scholar]

2. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61:2035–2063. [PubMed] [Google Scholar]

3. Gazák R, Walterová D, Kren V. Silybin and silymarin--new and emerging applications in medicine. Curr Med Chem. 2007;14:315–338. [PubMed] [Google Scholar]

4. Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases--a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol. 2005;100:2583–2591. [PubMed] [Google Scholar]

5. Seeff LB. Are herbals as safe as their advocates believe? J Hepatol. 2009;50:13–16. [PubMed] [Google Scholar]

6. Gazák R, Walterová D, Kren V. Silybin and silymarin--new and emerging applications in medicine. Curr Med Chem. 2007;14:315–338. [PubMed] [Google Scholar]

7. Tamayo C, Diamond S. Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.) Integr Cancer Ther. 2007;6:146–157. [PubMed] [Google Scholar]

8. Stickel F, Schuppan D. Herbal medicine in the treatment of liver diseases. Dig Liver Dis. 2007;39:293–304. [PubMed] [Google Scholar]

9. Fehér J, Lengyel G. [Silymarin in the treatment of chronic liver diseases: past and future] Orv Hetil. 2008;149:2413–2418. [PubMed] [Google Scholar]

10. Tindle HA, Davis RB, Phillips RS, Eisenberg DM. Trends in use of complementary and alternative medicine by US adults: 1997-2002. Altern Ther Health Med. 2005;11:42–49. [PubMed] [Google Scholar]

11. Kim NC, Graf TN, Sparacino CM, Wani MC, Wall ME. Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum) Org Biomol Chem. 2003;1:1684–1689. [PubMed] [Google Scholar]

12. Kvasnicka F, Bíba B, Sevcík R, Voldrich M, Krátká J. Analysis of the active components of silymarin. J Chromatogr A. 2003;990:239–245. [PubMed] [Google Scholar]

13. Lee DY, Liu Y. Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, Isolated from Silybum marianum (milk thistle) J Nat Prod. 2003;66:1171–1174. [PubMed] [Google Scholar]

14. Lee JI, Hsu BH, Wu D, Barrett JS. Separation and characterization of silybin, isosilybin, silydianin and silychristin in milk thistle extract by liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr A. 2006;1116:57–68. [PubMed] [Google Scholar]

15. Li W, Han J, Li Z, Li X, Zhou S, Liu C. Preparative chromatographic purification of diastereomers of silybin and their quantification in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;862:51–57. [PubMed] [Google Scholar]

16. Lee JI, Narayan M, Barrett JS. Analysis and comparison of active constituents in commercial standardized silymarin extracts by liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;845:95–103. [PubMed] [Google Scholar]

17. Wen Z, Dumas TE, Schrieber SJ, Hawke RL, Fried MW, Smith PC. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos. 2008;36:65–72. [PubMed] [Google Scholar]

18. Han YH, Lou HX, Ren DM, Sun LR, Ma B, Ji M. Stereoselective metabolism of silybin diastereoisomers in the glucuronidation process. J Pharm Biomed Anal. 2004;34:1071–1078. [PubMed] [Google Scholar]

19. Barnes S, Prasain JK, Wang CC, Moore DR 2nd. Applications of LC-MS in the study of the uptake, distribution, metabolism and excretion of bioactive polyphenols from dietary supplements. Life Sci. 2006;78:2054–2059. [PubMed] [Google Scholar]

20. Yanyu X, Yunmei S, Zhipeng C, Qineng P. The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats. Int J Pharm. 2006;307:77–82. [PubMed] [Google Scholar]

21. Wu JW, Lin LC, Hung SC, Chi CW, Tsai TH. Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. J Pharm Biomed Anal. 2007;45:635–641. [PubMed] [Google Scholar]

22. Tang N, Wu D, Lu Y, Chen J, Zhang B, Wu W. A comparative study on the stability of silybin and that in silymarin in buffers and biological fluids. Drug Metab Lett. 2009;3:115–119. [PubMed] [Google Scholar]

23. Yanyu X, Yunmei S, Zhipeng C, Qineng P. The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats. Int J Pharm. 2006;307:77–82. [PubMed] [Google Scholar]

24. Song Y, Zhuang J, Guo J, Xiao Y, Ping Q. Preparation and properties of a silybin-phospholipid complex. Pharmazie. 2008;63:35–42. [PubMed] [Google Scholar]

25. Jia LJ, Zhang DR, Li ZY, Feng FF, Wang YC, Dai WT, Duan CX, Zhang Q. Preparation and characterization of silybin-loaded nanostructured lipid carriers. Drug Deliv. 2009:Epub ahead of print. [PubMed] [Google Scholar]

26. Kidd P, Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos) Altern Med Rev. 2005;10:193–203. [PubMed] [Google Scholar]

27. Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, Harrison GS, Pierson AS, Agarwal R, Glodé LM. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs. 2007;25:139–146. [PubMed] [Google Scholar]

28. Voinovich D, Perissutti B, Magarotto L, Ceschia D, Guiotto P, Bilia AR. Solid state mechanochemical simultaneous activation of the constituents of the Silybum marianum phytocomplex with crosslinked polymers. J Pharm Sci. 2009;98:215–228. [PubMed] [Google Scholar]

29. Kidd PM. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Altern Med Rev. 2009;14:226–246. [PubMed] [Google Scholar]

30. Bai TC, Yan GB, Hu J, Zhang HL, Huang CG. Solubility of silybin in aqueous poly(ethylene glycol) solution. Int J Pharm. 2006;308:100–106. [PubMed] [Google Scholar]

31. Kosina P, Kren V, Gebhardt R, Grambal F, Ulrichová J, Walterová D. Antioxidant properties of silybin glycosides. Phytother Res. 2002;16 Suppl 1:S33–S39. [PubMed] [Google Scholar]

32. Huber A, Thongphasuk P, Erben G, Lehmann WD, Tuma S, Stremmel W, Chamulitrat W. Significantly greater antioxidant anticancer activities of 2,3-dehydrosilybin than silybin. Biochim Biophys Acta. 2008;1780:837–847. [PubMed] [Google Scholar]

33. Yang L, Gong J, Wang F, Zhang Y, Wang Y, Hao X, Wu X, Bai H, Stöckigt J, Zhao Y. Synthesis and antioxidant evaluation of novel silybin analogues. J Enzyme Inhib Med Chem. 2006;21:399–404. [PubMed] [Google Scholar]

34. Basiglio CL, Sánchez Pozzi EJ, Mottino AD, Roma MG. Differential effects of silymarin and its active component silibinin on plasma membrane stability and hepatocellular lysis. Chem Biol Interact. 2009;179:297–303. [PubMed] [Google Scholar]

35. Fu H, Lin M, Muroya Y, Hata K, Katsumura Y, Yokoya A, Shikazono N, Hatano Y. Free radical scavenging reactions and antioxidant activities of silybin: mechanistic aspects and pulse radiolytic studies. Free Radic Res. 2009;43:887–897. [PubMed] [Google Scholar]

36. Zhao J, Agarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis. 1999;20:2101–2108. [PubMed] [Google Scholar]

37. Hoh C, Boocock D, Marczylo T, Singh R, Berry DP, Dennison AR, Hemingway D, Miller A, West K, Euden S, et al. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin Cancer Res. 2006;12:2944–2950. [PubMed] [Google Scholar]

38. Kim YC, Kim EJ, Lee ED, Kim JH, Jang SW, Kim YG, Kwon JW, Kim WB, Lee MG. Comparative bioavailability of silibinin in healthy male volunteers. Int J Clin Pharmacol Ther. 2003;41:593–596. [PubMed] [Google Scholar]

39. Barzaghi N, Crema F, Gatti G, Pifferi G, Perucca E. Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet. 1990;15:333–338. [PubMed] [Google Scholar]

40. Gatti G, Perucca E. Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers. Int J Clin Pharmacol Ther. 1994;32:614–617. [PubMed] [Google Scholar]

41. Liu X, Zhang Y, Tang X, Zhang H. Determination of entrapment efficiency and drug phase distribution of submicron emulsions loaded silybin. J Microencapsul. 2009;26:180–186. [PubMed] [Google Scholar]

42. Li W, Gao J, Zhao HZ, Liu CX. Development of a HPLC-UV assay for silybin-phosphatidylcholine complex (silybinin capsules) and its pharmacokinetic study in healthy male Chinese volunteers. Eur J Drug Metab Pharmacokinet. 2006;31:265–270. [PubMed] [Google Scholar]

43. http://www.indena.com/pdf/ephytosome.pdf .

44. Orlando R, Fragasso A, Lampertico M, Marena C. Silybin kinetics in patients with liver cirrhosis: a comparative study of a silybin-phosphatidylcholine complex and silymarin. Metab Sci Res. 1990;18:861–863. [Google Scholar]

45. Wu JW, Lin LC, Hung SC, Lin CH, Chi CW, Tsai TH. Hepatobiliary excretion of silibinin in normal and liver cirrhotic rats. Drug Metab Dispos. 2008;36:589–596. [PubMed] [Google Scholar]

46. Hawke RL, Schrieber SJ, Soule TA, Wen Z, Smith PC, Reddy KR, Wahed AS, Belle SH, Afdhal NH, Navarro VJ, et al. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol. 2010;50:434–449. [PMC free article] [PubMed] [Google Scholar]

47. Schrieber SJ, Wen Z, Vourvahis M, Smith PC, Fried MW, Kashuba AD, Hawke RL. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab Dispos. 2008;36:1909–1916. [PubMed] [Google Scholar]

48. Gunaratna C, Zhang T. Application of liquid chromatography-electrospray ionization-ion trap mass spectrometry to investigate the metabolism of silibinin in human liver microsomes. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;794:303–310. [PubMed] [Google Scholar]

49. Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, Strom SC. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos. 2000;28:1270–1273. [PubMed] [Google Scholar]

50. Wang B, Zhou SF. Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16:4066–4218. [PubMed] [Google Scholar]

51. Wang B, Zhou SF. Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16:4066–4218. [PubMed] [Google Scholar]

52. Brantley SJ, Oberlies NH, Kroll DJ, Paine MF. Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. J Pharmacol Exp Ther. 2010;332:1081–1087. [PMC free article] [PubMed] [Google Scholar]

53. Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry WB, Breen P, Carrier DJ, Cheboyina S. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol. 2006;46:201–213. [PMC free article] [PubMed] [Google Scholar]

54. Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos. 2004;32:587–594. [PubMed] [Google Scholar]

55. Piscitelli SC, Formentini E, Burstein AH, Alfaro R, Jagannatha S, Falloon J. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy. 2002;22:551–556. [PubMed] [Google Scholar]

56. Mills E, Wilson K, Clarke M, Foster B, Walker S, Rachlis B, DeGroot N, Montori VM, Gold W, Phillips E, et al. Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. Eur J Clin Pharmacol. 2005;61:1–7. [PubMed] [Google Scholar]

57. Miranda SR, Lee JK, Brouwer KL, Wen Z, Smith PC, Hawke RL. Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2) Drug Metab Dispos. 2008;36:2219–2226. [PMC free article] [PubMed] [Google Scholar]

58. Chang JC, Wu YT, Lee WC, Lin LC, Tsai TH. Herb-drug interaction of silymarin or silibinin on the pharmacokinetics of trazodone in rats. Chem Biol Interact. 2009;182:227–232. [PubMed] [Google Scholar]

59. Dvorák Z, Kosina P, Walterová D, Simánek V, Bachleda P, Ulrichová J. Primary cultures of human hepatocytes as a tool in cytotoxicity studies: cell protection against model toxins by flavonolignans obtained from Silybum marianum. Toxicol Lett. 2003;137:201–212. [PubMed] [Google Scholar]

60. Kroll DJ, Shaw HS, Oberlies NH. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther. 2007;6:110–119. [PubMed] [Google Scholar]

61. Wu JW, Lin LC, Tsai TH. Drug-drug interactions of silymarin on the perspective of pharmacokinetics. J Ethnopharmacol. 2009;121:185–193. [PubMed] [Google Scholar]

62. Comelli MC, Mengs U, Schneider C, Prosdocimi M. Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy. Integr Cancer Ther. 2007;6:120–129. [PubMed] [Google Scholar]

63. Chen Y, Xie S, Chen S, Zeng S. Glucuronidation of flavonoids by recombinant UGT1A3 and UGT1A9. Biochem Pharmacol. 2008;76:416–425. [PubMed] [Google Scholar]

64. Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song PF, Hubbard MA, Tong Y, Cheboyina S. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos. 2006;34:69–74. [PMC free article] [PubMed] [Google Scholar]

65. Trouillas P, Marsal P, Svobodová A, Vostálová J, Gazák R, Hrbác J, Sedmera P, Kren V, Lazzaroni R, Duroux JL, et al. Mechanism of the antioxidant action of silybin and 2,3-dehydrosilybin flavonolignans: a joint experimental and theoretical study. J Phys Chem A. 2008;112:1054–1063. [PubMed] [Google Scholar]

66. Dehmlow C, Erhard J, de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology. 1996;23:749–754. [PubMed] [Google Scholar]

67. Rolo AP, Oliveira PJ, Moreno AJ, Palmeira CM. Protection against post-ischemic mitochondrial injury in rat liver by silymarin or TUDC. Hepatol Res. 2003;26:217–224. [PubMed] [Google Scholar]

68. Comoglio A, Tomasi A, Malandrino S, Poli G, Albano E. Scavenging effect of silipide, a new silybin-phospholipid complex, on ethanol-derived free radicals. Biochem Pharmacol. 1995;50:1313–1316. [PubMed] [Google Scholar]

69. Carini R, Comoglio A, Albano E, Poli G. Lipid peroxidation and irreversible damage in the rat hepatocyte model. Protection by the silybin-phospholipid complex IdB 1016. Biochem Pharmacol. 1992;43:2111–2115. [PubMed] [Google Scholar]

70. Ligeret H, Brault A, Vallerand D, Haddad Y, Haddad PS. Antioxidant and mitochondrial protective effects of silibinin in cold preservation-warm reperfusion liver injury. J Ethnopharmacol. 2008;115:507–514. [PubMed] [Google Scholar]

71. Bosisio E, Benelli C, Pirola O. Effect of the flavanolignans of Silybum marianum L. on lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes. Pharmacol Res. 1992;25:147–154. [PubMed] [Google Scholar]

72. Fu H, Katsumura Y, Lin M, Hata K, Muroya Y, Hatano Y. Fast repair activities towards dGMP hydroxyl radical adducts by silybin and its analogues. J Radiat Res (Tokyo) 2008;49:609–614. [PubMed] [Google Scholar]

73. Täger M, Dietzmann J, Thiel U, Hinrich Neumann K, Ansorge S. Restoration of the cellular thiol status of peritoneal macrophages from CAPD patients by the flavonoids silibinin and silymarin. Free Radic Res. 2001;34:137–151. [PubMed] [Google Scholar]

74. Comoglio A, Leonarduzzi G, Carini R, Busolin D, Basaga H, Albano E, Tomasi A, Poli G, Morazzoni P, Magistretti MJ. Studies on the antioxidant and free radical scavenging properties of IdB 1016 a new flavanolignan complex. Free Radic Res Commun. 1990;11:109–115. [PubMed] [Google Scholar]

75. van Pelt JF, Verslype C, Crabbé T, Zaman Z, Fevery J. Primary human hepatocytes are protected against prolonged and repeated exposure to ethanol by silibinin-dihemisuccinate. Alcohol Alcohol. 2003;38:411–414. [PubMed] [Google Scholar]

76. Borsari M, Gabbi C, Ghelfi F, Grandi R, Saladini M, Severi S, Borella F. Silybin, a new iron-chelating agent. J Inorg Biochem. 2001;85:123–129. [PubMed] [Google Scholar]

77. Pietrangelo A, Montosi G, Garuti C, Contri M, Giovannini F, Ceccarelli D, Masini A. Iron-induced oxidant stress in nonparenchymal liver cells: mitochondrial derangement and fibrosis in acutely iron-dosed gerbils and its prevention by silybin. J Bioenerg Biomembr. 2002;34:67–79. [PubMed] [Google Scholar]

78. Gharagozloo M, Khoshdel Z, Amirghofran Z. The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: a comparison with desferrioxamine. Eur J Pharmacol. 2008;589:1–7. [PubMed] [Google Scholar]

79. Bremner P, Heinrich M. Natural products as targeted modulators of the nuclear factor-kappaB pathway. J Pharm Pharmacol. 2002;54:453–472. [PubMed] [Google Scholar]

80. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer. 2007;121:2381–2386. [PubMed] [Google Scholar]

81. Yoo HG, Jung SN, Hwang YS, Park JS, Kim MH, Jeong M, Ahn SJ, Ahn BW, Shin BA, Park RK, et al. Involvement of NF-kappaB and caspases in silibinin-induced apoptosis of endothelial cells. Int J Mol Med. 2004;13:81–86. [PubMed] [Google Scholar]

82. Momeny M, Khorramizadeh MR, Ghaffari SH, Yousefi M, Yekaninejad MS, Esmaeili R, Jahanshiri Z, Nooridaloii MR. Effects of silibinin on cell growth and invasive properties of a human hepatocellular carcinoma cell line, HepG-2, through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation. Eur J Pharmacol. 2008;591:13–20. [PubMed] [Google Scholar]

83. Gharagozloo M, Velardi E, Bruscoli S, Agostini M, Di Sante M, Donato V, Amirghofran Z, Riccardi C. Silymarin suppress CD4+ T cell activation and proliferation: effects on NF-kappaB activity and IL-2 production. Pharmacol Res. 2010;61:405–409. [PubMed] [Google Scholar]

84. Schümann J, Prockl J, Kiemer AK, Vollmar AM, Bang R, Tiegs G. Silibinin protects mice from T cell-dependent liver injury. J Hepatol. 2003;39:333–340. [PubMed] [Google Scholar]

85. Di Sario A, Bendia E, Taffetani S, Omenetti A, Candelaresi C, Marzioni M, De Minicis S, Benedetti A. Hepatoprotective and antifibrotic effect of a new silybin-phosphatidylcholine-Vitamin E complex in rats. Dig Liver Dis. 2005;37:869–876. [PubMed] [Google Scholar]

86. Chittezhath M, Deep G, Singh RP, Agarwal C, Agarwal R. Silibinin inhibits cytokine-induced signaling cascades and down-regulates inducible nitric oxide synthase in human lung carcinoma A549 cells. Mol Cancer Ther. 2008;7:1817–1826. [PMC free article] [PubMed] [Google Scholar]

87. Lu P, Mamiya T, Lu LL, Mouri A, Niwa M, Hiramatsu M, Zou LB, Nagai T, Ikejima T, Nabeshima T. Silibinin attenuates amyloid beta(25-35) peptide-induced memory impairments: implication of inducible nitric-oxide synthase and tumor necrosis factor-alpha in mice. J Pharmacol Exp Ther. 2009;331:319–326. [PubMed] [Google Scholar]

88. Shanmugam K, Holmquist L, Steele M, Stuchbury G, Berbaum K, Schulz O, Benavente García O, Castillo J, Burnell J, Garcia Rivas V, et al. Plant-derived polyphenols attenuate lipopolysaccharide-induced nitric oxide and tumour necrosis factor production in murine microglia and macrophages. Mol

Nutr Food Res. 2008;52:427–438. [PubMed] [Google Scholar]

89. Verschoyle RD, Greaves P, Patel K, Marsden DA, Brown K, Steward WP, Gescher AJ. Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: relationship with silibinin levels. Eur J Cancer. 2008;44:898–906. [PubMed] [Google Scholar]

90. Deep G, Oberlies NH, Kroll DJ, Agarwal R. Identifying the differential effects of silymarin constituents on cell growth and cell cycle regulatory molecules in human prostate cancer cells. Int J Cancer. 2008;123:41–50. [PubMed] [Google Scholar]

91. Wang HJ, Tashiro S, Onodera S, Ikejima T. Inhibition of insulin-like growth factor 1 receptor signaling enhanced silibinin-induced activation of death receptor and mitochondrial apoptotic pathways in human breast cancer MCF-7 cells. J Pharmacol Sci. 2008;107:260–269. [PubMed] [Google Scholar]

92. Singh RP, Gu M, Agarwal R. Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res. 2008;68:2043–2050. [PubMed] [Google Scholar]

93. Morishima C, Shuhart MC, Wang CC, Paschal DM, Apodaca MC, Liu Y, Sloan DD, Graf TN, Oberlies NH, Lee DY, et al. Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology. 2010;138:671–681, 681.e1-2. [PMC free article] [PubMed] [Google Scholar]

94. Gazák R, Purchartová K, Marhol P, Zivná L, Sedmera P, Valentová K, Kato N, Matsumura H, Kaihatsu K, Kren V. Antioxidant and antiviral activities of silybin fatty acid conjugates. Eur J Med Chem. 2010;45:1059–1067. [PubMed] [Google Scholar]

95. Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, Lee DY. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology. 2007;132:1925–1936. [PubMed] [Google Scholar]

96. Trappoliere M, Caligiuri A, Schmid M, Bertolani C, Failli P, Vizzutti F, Novo E, di Manzano C, Marra F, Loguercio C, et al. Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol. 2009;50:1102–1111. [PubMed] [Google Scholar]

97. Muriel P, Moreno MG, Hernández Mdel C, Chávez E, Alcantar LK. Resolution of liver fibrosis in chronic CCl4 administration in the rat after discontinuation of treatment: effect of silymarin, silibinin, colchicine and trimethylcolchicinic acid. Basic Clin Pharmacol Toxicol. 2005;96:375–380. [PubMed] [Google Scholar]

98. Lieber CS, Leo MA, Cao Q, Ren C, DeCarli LM. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol. 2003;37:336–339. [PubMed] [Google Scholar]

99. Loguercio C, Federico A, Trappoliere M, Tuccillo C, de Sio I, Di Leva A, Niosi M, D'Auria MV, Capasso R, Del Vecchio Blanco C. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci. 2007;52:2387–2395. [PubMed] [Google Scholar]

100. Nomura M, Takahashi T, Nagata N, Tsutsumi K, Kobayashi S, Akiba T, Yokogawa K, Moritani S, Miyamoto K. Inhibitory mechanisms of flavonoids on insulin-stimulated glucose uptake in MC3T3-G2/PA6 adipose cells. Biol Pharm Bull. 2008;31:1403–1409. [PubMed] [Google Scholar]

101. Detaille D, Sanchez C, Sanz N, Lopez-Novoa JM, Leverve X, El-Mir MY. Interrelation between the inhibition of glycolytic flux by silibinin and the lowering of mitochondrial ROS production in perifused rat hepatocytes. Life Sci. 2008;82:1070–1076. [PubMed] [Google Scholar]

102. Guigas B, Naboulsi R, Villanueva GR, Taleux N, Lopez-Novoa JM, Leverve XM, El-Mir MY. The flavonoid silibinin decreases glucose-6-phosphate hydrolysis in perfused rat hepatocytes by an inhibitory effect on glucose-6-phosphatase. Cell Physiol Biochem. 2007;20:925–934. [PubMed] [Google Scholar]

103. Maghrani M, Zeggwagh NA, Lemhadri A, El Amraoui M, Michel JB, Eddouks M. Study of the hypoglycaemic activity of Fraxinus excelsior and Silybum marianum in an animal model of type 1 diabetes mellitus. J Ethnopharmacol. 2004;91:309–316. [PubMed] [Google Scholar]

104. Lirussi F, Beccarello A, Zanette G, De Monte A, Donadon V, Velussi M, Crepaldi G. Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent. Diabetes Nutr Metab. 2002;15:222–231. [PubMed] [Google Scholar]

105. Huseini HF, Larijani B, Heshmat R, Fakhrzadeh H, Radjabipour B, Toliat T, Raza M. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res. 2006;20:1036–1039. [PubMed] [Google Scholar]

106. Mokhtari MJ, Motamed N, Shokrgozar MA. Evaluation of silibinin on the viability, migration and adhesion of the human prostate adenocarcinoma (PC-3) cell line. Cell Biol Int. 2008;32:888–892. [PubMed] [Google Scholar]

107. Raina K, Rajamanickam S, Singh RP, Deep G, Chittezhath M, Agarwal R. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2008;68:6822–6830. [PMC free article] [PubMed] [Google Scholar]

108. Verschoyle RD, Greaves P, Patel K, Marsden DA, Brown K, Steward WP, Gescher AJ. Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: relationship with silibinin levels. Eur J Cancer. 2008;44:898–906. [PubMed] [Google Scholar]

109. Lah JJ, Cui W, Hu KQ. Effects and mechanisms of silibinin on human hepatoma cell lines. World J Gastroenterol. 2007;13:5299–5305. [PMC free article] [PubMed] [Google Scholar]

110. Tyagi A, Raina K, Singh RP, Gu M, Agarwal C, Harrison G, Glode LM, Agarwal R. Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice. Mol Cancer Ther. 2007;6:3248–3255. [PubMed] [Google Scholar]

111. Singh RP, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res. 2002;62:3063–3069. [PubMed] [Google Scholar]

112. Roy S, Kaur M, Agarwal C, Tecklenburg M, Sclafani RA, Agarwal R. p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol Cancer Ther. 2007;6:2696–2707. [PubMed] [Google Scholar]

113. Tyagi A, Sharma Y, Agarwal C, Agarwal R. Silibinin impairs constitutively active TGFalpha-EGFR autocrine loop in advanced human prostate carcinoma cells. Pharm Res. 2008;25:2143–2150. [PubMed] [Google Scholar]

114. Wang HJ, Tashiro S, Onodera S, Ikejima T. Inhibition of insulin-like growth factor 1 receptor signaling enhanced silibinin-induced activation of death receptor and mitochondrial apoptotic pathways in human breast cancer MCF-7 cells. J Pharmacol Sci. 2008;107:260–269. [PubMed] [Google Scholar]

115. Hannay JA, Yu D. Silibinin: a thorny therapeutic for EGF-R expressing tumors? Cancer Biol Ther. 2003;2:532–533. [PubMed] [Google Scholar]

116. Thongphasuk P, Stremmel W, Chamulitrat W. 2,3-dehydrosilybin is a better DNA topoisomerase I inhibitor than its parental silybin. Chemotherapy. 2009;55:42–48. [PubMed] [Google Scholar]

117. Plísková M, Vondrácek J, Kren V, Gazák R, Sedmera P, Walterová D, Psotová J, Simánek V, Machala M. Effects of silymarin flavonolignans and synthetic silybin derivatives on estrogen and aryl hydrocarbon receptor activation. Toxicology. 2005;215:80–89. [PubMed] [Google Scholar]

118. Varghese L, Agarwal C, Tyagi A, Singh RP, Agarwal R. Silibinin efficacy against human hepatocellular carcinoma. Clin Cancer Res. 2005;11:8441–8448. [PubMed] [Google Scholar]

119. Angeli JP, Barcelos GR, Serpeloni JM, Barbosa F Jr, Nersesyan A, Mantovani MS. Evaluation of the genotoxic and anti-genotoxic activities of silybin in human hepatoma cells (HepG2) Mutagenesis. 2010;25:223–229. [PubMed] [Google Scholar]

120. Hogan FS, Krishnegowda NK, Mikhailova M, Kahlenberg MS. Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer. J Surg Res. 2007;143:58–65. [PubMed] [Google Scholar]

121. Sangeetha N, Felix AJ, Nalini N. Silibinin modulates biotransforming microbial enzymes and prevents 1,2-dimethylhydrazine-induced preneoplastic changes in experimental colon cancer. Eur J Cancer Prev. 2009;18:385–394. [PubMed] [Google Scholar]

122. Singh RP, Tyagi A, Sharma G, Mohan S, Agarwal R. Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin. Clin Cancer Res. 2008;14:300–308. [PubMed] [Google Scholar]

123. Lin CJ, Sukarieh R, Pelletier J. Silibinin inhibits translation initiation: implications for anticancer therapy. Mol Cancer Ther. 2009;8:1606–1612. [PubMed] [Google Scholar]

124. Salhanick SD, Wax PM, Schneider SM. In response to Tong TC, et al Comparative treatment of alpha-amanitin poisoning with N-acetylcysteine, benzylpenicillin, cimetidine, thioctic acid, and silybin in a murine model. Ann Emerg Med. 2008;52:184–185; author reply 185. [PubMed] [Google Scholar]

125. Enjalbert F, Rapior S, Nouguier-Soulé J, Guillon S, Amouroux N, Cabot C. Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol. 2002;40:715–757. [PubMed] [Google Scholar]

126. Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence VA. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am J Med. 2002;113:506–515. [PubMed] [Google Scholar]

127. Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev. 2005:CD003620. [PubMed] [Google Scholar]

128. Dhiman RK, Chawla YK. Herbal medicines for liver diseases. Dig Dis Sci. 2005;50:1807–1812. [PubMed] [Google Scholar]

129. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, Lindsay KL, Lok AS, Di Bisceglie AM, et al. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology. 2008;47:605–612. [PubMed] [Google Scholar]

130. Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat. 2005;12:559–567. [PubMed] [Google Scholar]

131. Torres M, Rodríguez-Serrano F, Rosario DJ, Rodríguez-Perez F, Toro DH. Does Silybum marianum play a role in the treatment of chronic hepatitis C? P R Health Sci J. 2004;23:69–74. [PubMed] [Google Scholar]

132. El-Zayadi AR, Attia M, Badran HM, El-Tawil A, Zalata K, Barakat E, Selim O, El-Nakeeb A, Saied A. Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy. Liver Int. 2005;25:746–751. [PubMed] [Google Scholar]

133. Melhem A, Stern M, Shibolet O, Israeli E, Ackerman Z, Pappo O, Hemed N, Rowe M, Ohana H, Zabrecky G, et al. Treatment of chronic hepatitis C virus infection *via* antioxidants: results of a phase I clinical trial. J Clin Gastroenterol. 2005;39:737–742. [PubMed] [Google Scholar]

134. Falasca K, Ucciferri C, Mancino P, Vitacolonna E, De Tullio D, Pizzigallo E, Conti P, Vecchiet J. Treatment with silybin-vitamin E-phospholipid complex in patients with hepatitis C infection. J Med Virol. 2008;80:1900–1906. [PubMed] [Google Scholar]

135. Gordon A, Hobbs DA, Bowden DS, Bailey MJ, Mitchell J, Francis AJ, Roberts SK. Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. J Gastroenterol Hepatol. 2006;21:275–280. [PubMed] [Google Scholar]

136. Strickland GT, Tanamly MD, Tadros F, Labeeb S, Makld H, Nessim D, Mikhail N, Magder LS, Afdhal NH, Medhat A, et al. Two-year results of a randomised double-blinded trial evaluating silymarin for chronic hepatitis C. Dig Liver Dis. 2005;37:542–543. [PubMed] [Google Scholar]

137. Tanamly MD, Tadros F, Labeeb S, Makld H, Shehata M, Mikhail N, Abdel-Hamid M, Shehata M, Abu-Baki L, Medhat A, et al. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig Liver Dis. 2004;36:752–759. [PubMed] [Google Scholar]

138. Bares JM, Berger J, Nelson JE, Messner DJ, Schildt S, Standish LJ, Kowdley KV. Silybin treatment is associated with reduction in serum ferritin in patients with chronic hepatitis C. J Clin Gastroenterol. 2008;42:937–944. [PubMed] [Google Scholar]

139. Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, Schöniger-Hekele M, Holzmann H, Steindl-Munda P. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology. 2008;135:1561–1567. [PubMed] [Google Scholar]

140. Biermer M, Berg T. Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin. Gastroenterology. 2009;137:390–391. [PubMed] [Google Scholar]

141. Federico A, Trappoliere M, Tuccillo C, de Sio I, Di Leva A, Del Vecchio Blanco C, Loguercio C. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. Gut. 2006;55:901–902. [PMC free article] [PubMed] [Google Scholar]

142. Federico A, Niosi M, Vecchio Blanco CD, Loguercio C. Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs. 2008;13:145–158. [PubMed] [Google Scholar]

143. Serviddio G, Bellanti F, Giudetti AM, Gnoni GV, Petrella A, Tamborra R, Romano AD, Rollo T, Vendemiale G, Altomare E. A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis. J Pharmacol Exp Ther. 2010;332:922–932. [PubMed] [Google Scholar]

144. Loguercio C, Andreone P, Brisc C, Chiaramonte M, de Sio I, FedericoA, Floreani A, Freni MA, Grieco A, Lobello S, Milani S, Okolicsanyi L, Portincasa P, Smedile A, Spadaro A, Sporea I, Sorrentino P, Vecchione R, Del Vecchio Blanco C. Effect of silybin in patients with chronic hepatitis: preliminary results of a multicentre randomized controlled trial vs placebo. Gastroenterology. 2010;138 Suppl 1:8800. [Google Scholar]

145. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010;14:1–21, vii. [PubMed] [Google Scholar]

146. Vailati A, Aristia L, Sozze' E, Milani F, Inglese V, Galenda P. Randomized open study of the dose-effect relationship of a short course of IdB in 1016 in patients with viral or alcoholic hepatitis. Fitoterapia. 1993;64:219–228. [Google Scholar]

147. Buzzelli G, Moscarella S, Giusti A, Duchini A, Marena C, Lampertico M. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol. 1993;31:456–460. [PubMed] [Google Scholar]

148. Buzzelli G, Moscarella S, Barbagli S, Marena C, Gentilini P. Therapeutic effect of Silipide in patients with chronic hepatitis C nonresponders (NRs) to interferon (IFN) treatment [abstract] J Hepatol. 1994;21(Suppl 1):S100. [Google Scholar]